Newly published head-to-head data show Stiolto Respimat improved lung function across range of measures
Stiolto Respimat was compared with a European formulation of a combination of a long-acting beta agonist, salmeterol, and an inhaled corticosteroid, fluticasone propionate.
Boehringer Ingelheim Pharmaceuticals has announced the publication of data that show Stiolto Respimat improved lung function across a range of measures (FEV(1) AUC(0-12), FEV(1) AUC(0-24), FEV(1) AUC(12-24, ) peak(0-3 ) FEV(1 ) and trough FEV(1)) compared with a European formulation of a combination of a long-acting beta agonist (LABA), salmeterol, and an inhaled corticosteroid (ICS), fluticasone propionate (50/500 mcg, 50/250 mcg).
Published online in Journal of Chronic Obstructive Pulmonary Disease (COPD), these data are from the ENERGITO study, which investigated the impact of Stiolto Respimat on lung function among moderate to severe COPD patients.
"The publication of these results further demonstrates the ability of Stiolto Respimat to safely and effectively improve lung function in COPD patients," said James Donohue, MD Professor of Medicine and Former Chief of the Division of Pulmonary & Critical Care Medicine at the University of North Carolina at Chapel Hill School of Medicine. "These newly published data show a lung function improvement among COPD patients with Stiolto Respimat across a range of commonly used measures of lung function."
Long-acting beta2-adrenergic agonists, such as olodaterol, one of the active ingredients in Stiolto Respimat, increase the risk of asthma-related death. Stiolto Respimat is not indicated for asthma and should not be initiated in acutely deteriorating COPD patients or for the relief of acute symptoms. Stiolto Respimat is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product. As with other inhaled medicines, Stiolto Respimat may cause paradoxical bronchospasm that may be life-threatening. The most common adverse reactions were nasopharyngitis, cough and back pain.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance